Antimicrobial Activity of Dequalinium Chloride against Leading Germs of Vaginal Infections

Casa, Vera Della; Noll, Harald; Gonser, Susanne; Grob, P.; Graf, Federico; Pohlig, Gabriele

doi:10.1055/s-0031-1299954

Cited by 21 publications

(30 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DQC is an anti-infective agent with a different mode of action, targeting the microbial cytoplasm membrane and leading to release of cellular components [18]. Due to this general mode of action, DQC comprises a broader spectrum of antimicrobial activity than most antibiotics and exerts a rapid microbiocidal action against a variety of pathogens [16,17]. We have shown in our study that DQC is as effective as one of the recommended regimens with maybe a faster recovery of the normal vaginal flora.…”

Section: Discussionmentioning

confidence: 99%

“…Dequalinium chloride (DQC), a quaternary ammonium compound, has a wide range of antimicrobial activity against Gram-positive and -negative bacteria, fungi and protozoa [16,17]. Its primary mode of action is the disruption of cell permeability and the subsequent loss of enzymatic activity [18].…”

Section: Introductionmentioning

confidence: 99%

“…Its primary mode of action is the disruption of cell permeability and the subsequent loss of enzymatic activity [18]. The antimicrobial activity of DQC has been assessed in vitro, and the minimum inhibition concentrations against relevant vaginal pathogens have been established [16,17]. The clinical efficacy and safety of DQC in the form of a vaginal tablet (Fluomizin®) or vaginal ovula in the treatment of BV and VVC have been previously demonstrated [19,20].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin®) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety

Weissenbacher

Donders²,

Unzeitig³

et al. 2011

Gynecol Obstet Invest

View full text Add to dashboard Cite

Aims: To investigate if vaginal application of dequalinium chloride (DQC, Fluomizin®) is as effective as vaginal clindamycin (CLM) in the treatment of bacterial vaginosis (BV). Methods: This was a multinational, multicenter, single-blind, randomized trial in 15 centers, including 321 women. They were randomized to either vaginal DQC tablets or vaginal CLM cream. Follow-up visits were 1 week and 1 month after treatment. Clinical cure based on Amsel’s criteria was the primary outcome. Secondary outcomes were rate of treatment failures and recurrences, incidence of post-treatment vulvovaginal candidosis (VVC), lactobacillary grade (LBG), total symptom score (TSC), and safety. Results: Cure rates with DQC (C1: 81.5%, C2: 79.5%) were as high as with CLM (C1: 78.4%, C2: 77.6%). Thus, the treatment with DQC had equal efficacy as CLM cream. A trend to less common post-treatment VVC in the DQC-treated women was observed (DQC: 2.5%, CLM: 7.7%; p = 0.06). Both treatments were well tolerated with no serious adverse events occurring. Conclusion: Vaginal DQC has been shown to be equally effective as CLM cream, to be well tolerated with no systemic safety concerns, and is therefore a valid alternative therapy for women with BV [ClinicalTrials.gov, Med380104, NCT01125410].

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin®) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety

Weissenbacher

Donders²,

Unzeitig³

et al. 2011

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Dequalinium (DQ) is a bisquinoline compound widely used in infectious diseases (Kaufman 1981;Della Casa et al 2002). DQ salts have been investigated as a safe and effective approach for the treatment of malaria (Makler 1990).…”

Section: Introductionmentioning

confidence: 99%

Effect of dequalinium on the oxidative stress in Plasmodium berghei-infected erythrocytes

Rodrígues

Gamboa

2009

Parasitol Res

View full text Add to dashboard Cite

The bisquinoline drug dequalinium (DQ) has demonstrated remarkable activity against some infection diseases, including malaria. Oxidative stress represents a biochemical target for potential antimalarials. In this work, we have tested the ability of this compound to modify the oxidative status in Plasmodium berghei-infected erythrocytes. After hemolysis, activities of superoxide dismutase (SOD), catalase (CAT), glutathione cycle, and dehydrogenase enzymes were investigated. The activity of glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGLD) in infected cells were diminished by this drug compared to controls (300% and 80% approximately, respectively), while glutathione peroxidase (GPx), glutathione transferase (GST), and glutathione levels were also lowered. As a compensatory response, we could appreciate an increase of SOD activity (20% approximately) in infected cells treated with DQ; however, catalase was not affected by the compound. Lipid peroxidation was also decreased by this drug, protecting the cells from the hemolysis caused by the infection. In conclusion, oxidative stress represents a biochemical event which is modulated by DQ, interfering with the antioxidant regular activities in P. berghei infection.

show abstract

“…DQA is a classic broad bacteriostatic with anti-fungicidal and anti-protozoal activity [21, 22]. At a molecular level, DQA interrupts the interaction XIAP/Caspase-3 [9].…”

Section: Discussionmentioning

confidence: 99%

XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells

et al. 2014

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a neoplasia characterized by the rapid expansion of immature myeloid blasts in the bone marrow, and marked by poor prognosis and frequent relapse. As such, new therapeutic approaches are required for remission induction and prevention of relapse. Due to the higher chemotherapy sensitivity and limited life span of more differentiated AML blasts, differentiation-based therapies are a promising therapeutic approach. Based on public available gene expression profiles, a myeloid-specific differentiation-associated gene expression pattern was defined as the therapeutic target. A XIAP inhibitor (Dequalinium chloride, DQA) was identified in an in silico screening searching for small molecules that induce similar gene expression regulation. Treatment with DQA, similarly to Embelin (another XIAP inhibitor), induced cytotoxicity and differentiation in AML. XIAP inhibition differentially impaired cell viability of the most primitive AML blasts and reduced clonogenic capacity of AML cells, sparing healthy mature blood and hematopoietic stem cells. Taken together, these results suggest that XIAP constitutes a potential target for AML treatment and support the evaluation of XIAP inhibitors in clinical trials.

show abstract

Antimicrobial Activity of Dequalinium Chloride against Leading Germs of Vaginal Infections

Cited by 21 publications

References 11 publications

A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin®) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety

A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin®) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety

Effect of dequalinium on the oxidative stress in Plasmodium berghei-infected erythrocytes

XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells

Contact Info

Product

Resources

About